← Back to Search

Other

Drug Combinations for Lymphoma

Phase 1

Waitlist Available

Research Sponsored by Celgene

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up every 2-3 months until proof of tumor progression

Awards & highlights

Study Summary

This trial is testing different combinations of drugs to treat two types of lymphoma.

Who is the study for?

Adults over 18 with certain types of lymphoma (DLBCL or follicular) that have not responded well to standard treatments. They must have measurable disease, be in good physical condition, and meet specific blood test criteria. Men must agree to avoid donating sperm during and after the trial.Check my eligibility

What is being tested?

The study is testing combinations of new drugs (CC-122, CC-223, CC-292) with an existing drug called Rituximab for treating Diffuse Large B-cell Lymphoma and Follicular Lymphoma. It's the first time these combinations are being tested across multiple centers.See study design

What are the potential side effects?

Potential side effects may include reactions related to the immune system, digestive issues like pancreatitis or diarrhea, nerve damage symptoms such as peripheral neuropathy, changes in blood counts leading to increased infection risk or bleeding problems.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ every 2-3 months until proof of tumor progression

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~every 2-3 months until proof of tumor progression

This trial's timeline: 3 weeks for screening, Varies for treatment, and every 2-3 months until proof of tumor progression for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety

Secondary outcome measures

Efficacy

Pharmacokinetics - CC-223 and CC-292 interaction

Trial Design

4Treatment groups

Experimental Treatment

Group I: CC-292 + CC-223 +/- rituximabExperimental Treatment3 Interventions

CC-292 administered twice daily at 500 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Group II: CC-122 + rituximabExperimental Treatment2 Interventions

CC-122 administered orally once daily in combination with Rituximab.

Group III: CC-122 + CC-292 +/- rituximabExperimental Treatment3 Interventions

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-292 administered orally twice daily at 500 mg with or without Rituximab administered by IV once every 28 days

Group IV: CC-122 + CC-223 +/- rituximabExperimental Treatment3 Interventions

CC-122 administered orally once daily at 2mg or 3 mg in combination with CC-223 administered orally once daily at 20mg or 30 mg with or without Rituximab administered by IV once every 28 days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Spebrutinib

Not yet FDA approved

Rituximab

FDA approved

CC-223

Not yet FDA approved

Avadomide

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

CelgeneLead Sponsor

636 Previous Clinical Trials

128,797 Total Patients Enrolled

Michael Pourdehnad, MDStudy DirectorCelgene

1 Previous Clinical Trials

271 Total Patients Enrolled

Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb

1,506 Previous Clinical Trials

3,369,323 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could you detail any studies that have been conducted on CC-122 in the past?

"CC-122 was first studied in 1993 at the NIH Research Center, 9000 Rockville Pike. Thus far there have 821 finished trials, while 410 are still ongoing with a concentration of studies located in Nashville, TN."

Answered by AI

Could you please inform me of the number of sites offering this trial in state?

"The trial is currently enrolling from 16 sites that stretch across the United States of America, including Nashville, Santa Barbara and Rochester. To lessen travel burdens for participants it is recommended to choose a location closest to you if one exists."

Answered by AI

Has CC-122 been given the green light by the Food and Drug Administration?

"Based on the limited data available, CC-122's safety was given a score of 1. Since this is only Phase 1 trial, there is minimal evidence supporting its efficacy and security."

Answered by AI

What is the current capacity of participants for this clinical research?

"Unfortunately, recruitment for this trial has ended. It was first posted on December 18th 2013 and last edited November 17th 2022. Alternatives may be available as there are presently over 1700 open studies with lymphoma, large b-cell diffuse enrolments and 410 clinical trials actively recruiting patients for CC-122 treatment."

Answered by AI

Are there any available vacancies for potential research participants in this experiment?

"At present, this research project is no longer recruiting participants. Initially posted on December 18th 2013 and last revised in November 17th 2022, it is not an option for prospective patients. If you are looking to join a clinical trial related to lymphoma (large cell-diffuse) or CC-122 then there are currently 1,768 and 410 active studies respectively."

Answered by AI

In what applications is CC-122 commonly employed?

"CC-122 is typically utilized to treat diffuse large b-cell lymphoma (dlbcl). Additionally, it can be administered in management of conditions such as B-Cell Lymphomas, Polyangium and Pemphigus Vulgaris."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

2013. "Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02031419.